Getinet M Adinew, a graduate learner in the Pharmaceutical Sciences, will attend the Frontiers in Stem Cells in Cancer Advanced Training Course at Magee-Women’s Research Institute in Pittsburgh, PA, from July 18-24, 2021.
Frontiers In Stem Cells in Cancer is an annual advanced training course that trains promising physicians and scientists from predominantly underrepresented communities in sophisticated technologies using pluripotent stem cells for clinically relevant discoveries in cancer.
The purpose of this training course is to provide comprehensive and sophisticated training in research strategies and state-of-the-art methods on cellular, molecular and genetic approaches for advancing Cancer Stem Cell Research. The National Institute of Health sponsors this course.
Getinet is a second-year PhD candidate of Pharmacology/Toxicology in the laboratory of Dr. Karam F.A. Soliman, Associate Dean for Research & Graduate Studies and Distinguished Professor of Pharmaceutical Sciences. His research focus is the role of microRNA-200a in Thymoquinone activation of nuclear factor 2 erythroid related factor 2/Antioxidant Responsive Element (Nrf2/ ARE) Pathway in Triple-Negative Breast Cancer.
“I am very glad to attend this advanced training course,” said Getinet. “This event is beneficial for my research in that it will help me to deeply understand how cancer stem cells will contribute to the carcinogenesis of different types of cancer, particularly on Triple-Negative Breast cancer.”
After graduation, Getinet hopes to enter academic research institutions and focus on expanding his current PhD project by doing advanced molecular research to find potential treatment options for Triple Negative Breast cancer and other cancers.